Variable
|
Total study
population
N=1178
|
EF ≤ 35%
N=755
|
EF > 35%
N=423
|
P-Value
|
Age, years |
58.3 (11.6) |
58.2 (11.5) |
58.4 (11.7) |
0.7920 |
Male |
889 (75.5) |
594 (78.7) |
295 (69.7) |
0.0006 |
Caucasian |
962 (81.7) |
613 (81.2) |
349 (82.5) |
0.5761 |
Medical History |
|
|
|
|
Non-ischemic CM |
585 (49.7) |
338 (44.8) |
247 (58.4) |
<0.0001 a
|
NYHA Class III |
301 (25.6) |
199 (26.4) |
102 (24.1) |
0.3969 |
Baseline EF, % |
24.5 (6.7) |
23.4 (6.7) |
26.5 (6.3) |
<0.0001 b
|
Pulmonary disease |
195 (16.6) |
120 (15.9) |
75 (17.7) |
0.4159 |
Never smoker |
315 (26.7) |
193 (25.6) |
122 (28.8) |
0.4230 |
Hyperlipidemia |
645 (54.8) |
433 (57.4) |
212 (50.1) |
0.0167 |
Hypertension |
610 (51.8) |
375 (49.7) |
235 (55.6) |
0.0524 |
Stroke |
65 (5.5) |
43 (5.7) |
22 (5.2) |
0.7214 |
Diabetes |
316 (26.8) |
191 (25.3) |
125 (29.6) |
0.1140 |
NSVT |
236 (20.0) |
156 (20.7) |
80 (18.9) |
0.4717 |
Syncope |
87 (7.4) |
57 (7.55) |
30 (7.1) |
0.7733 |
QRS duration <120 ms |
691 (58.7) |
388 (51.4) |
303 (71.6) |
<0.0001 a
|
Atrial fibrillation by ECG |
71 (6.0) |
40 (5.3) |
31 (7.33) |
0.1601 |
Blood pressure - diastolic, mmHg |
71.3 (11.1) |
71.0 (10.9) |
71.9
(11.3) |
0.1893 |
Blood pressure - systolic, mmHg |
120.3 (19.5) |
118.7 (18.2) |
123.3
(21.2) |
0.0001 |
Pulse, beats/min |
74.0 (14.1) |
73.8 (13.8) |
74.4 (14.7) |
0.4716 |
Sodium, mg/dl |
139.3 (3.1) |
139.3 (3.1) |
139.4 (3.0) |
0.5656 |
Potassium, mEq/L |
4.4 (0.5) |
4.4 (0.5) |
4.4 (0.4) |
0.5656 |
Ace inhibitor |
992 (84.2) |
638 (84.5) |
354 (83.7) |
0.7127 |
Beta blocker |
817 (69.4) |
522 (69.1) |
295 (69.7) |
0.8301 |
Digoxin |
802 (68.1) |
533 (70.6) |
269 (63.6) |
0.0134 |
Diuretic (loop) |
936 (79.5) |
600 (79.5) |
336 (79.4) |
0.9878 |
Spironolactone |
202 (17.2) |
125 (16.6) |
77 (18.2) |
0.4718 |
Statins |
487 (41.3) |
328 (43.4) |
159 (37.6) |
0.0503 |
Months from CHF diagnosis |
40.0 (47.5) |
43.7 (47.5) |
33.49 (46.9) |
0.0004 |